HSD17B3-AS1

Across TCGA pan-cancer cohorts, HSD17B3-AS1 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of HSD17B3-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where HSD17B3-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types HSD17B3-AS1 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, KIRC, and LUSC are the cancer types where HSD17B3-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HSD17B3-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	II,III,IV	−0.408	<.001	8	view →
KIRC	All	All	+0.104	<.001	7	view →
LUSC	All	All	+0.191	<.001	4	view →
KICH	Female	All	−0.086	<.001	4	view →
CHOL	All	All	−0.235	.004	3	view →
STAD	All	All	+0.141	.003	3	view →
ESCA	All	II,III,IV	+0.435	.038	2	view →
BLCA	All	All	+0.141	.044	2	view →
LIHC	Female	III,IV	−0.228	.009	1	view →
HNSC	Male	IV	+0.094	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

HSD17B3-AS1–THCA

Open the THCA breakdown →